Cargando…
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration
BACKGROUND: Aromatase inhibitor (AI) therapy is being extensively used as postoperative adjuvant therapy in patients with hormone receptor-positive postmenopausal breast cancer. On the other hand, it has been reported that ovarian function was restored when AI was administered to patients who had un...
Autores principales: | Nagao, Taeko, Kira, Misako, Takahashi, Masako, Honda, Junko, Hirose, Toshiyuki, Tangoku, Akira, Zembutsu, Hitoshi, Nakamura, Yusuke, Sasa, Mitsunori |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779795/ https://www.ncbi.nlm.nih.gov/pubmed/19909552 http://dx.doi.org/10.1186/1477-7819-7-88 |
Ejemplares similares
-
Joint Symptoms, Aromatase Inhibitor-Related Adverse Reactions, Are Indirectly Associated with Decreased Serum Estradiol
por: Honda, Junko, et al.
Publicado: (2011) -
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia
por: Kanematsu, Miyuki, et al.
Publicado: (2011) -
A case of matrix-producing carcinoma of the breast
por: Hirose, Toshiyuki, et al.
Publicado: (2008) -
Aromatase inhibitors in post-menopausal endometriosis
por: Polyzos, Nikolaos P, et al.
Publicado: (2011) -
Sarcopenia and Menopause: The Role of Estradiol
por: Geraci, Annalisa, et al.
Publicado: (2021)